TransMedics Group (NASDAQ:TMDX) Releases Earnings Results

TransMedics Group (NASDAQ:TMDX) announced its quarterly earnings data on Thursday. The company reported $0.51 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.30 by $0.21, FiscalAI reports. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The firm had revenue of $203.01 million during the quarter, compared to analyst estimates of $178.06 million. During the same quarter in the prior year, the firm posted $0.66 earnings per share. TransMedics Group’s quarterly revenue was up 41.1% on a year-over-year basis.

Here are the key takeaways from TransMedics Group’s conference call:

• TransMedics reported a record $203 million in third-quarter revenue, up 41% year over year, with liver and heart case volumes rising despite seasonal softness and a 6% decline in U.S. deceased-donor volume. The company raised 2026 revenue guidance to $764 million–$774 million, including about $14 million from PAD Aviation.
• Management highlighted upcoming growth opportunities in heart and lung: FDA approved protocol amendments for ENHANCE Heart Part B and DENOVO Lung, with enrollment expected to begin in early 2027. The company also remains on track for OCS Kidney’s first-in-human clinical experience in the second half of 2027, though these programs have not yet contributed meaningful revenue.
• TransMedics won its first European transplant-logistics tender, in Italy’s Emilia-Romagna region, and plans to launch OCS NOP in Italy, the Netherlands, and Belgium in the first half of 2027. Management sees additional tenders as a potential source of growth, but did not quantify the first award.
• Third-quarter GAAP gross margin was not specified, but reported gross margin was 58.5%, down 40 basis points year over year, partly because lower-margin service revenue and PAD Aviation made up a larger share of sales. Excluding PAD, gross margin improved to 61.1%; management expects some normalization in service margins in the fourth quarter and kept its full-year adjusted operating-margin outlook at 12.5%–14% amid planned investment.
• Executives acknowledged softer October flight trends and said fourth-quarter guidance assumes no meaningful revenue contribution from ENHANCE Part B or DENOVO, as well as potential holiday-season effects. They characterized the outlook as conservative and said recent flight data alone may not reflect total transport activity.

TransMedics Group Stock Up 27.9%

Shares of NASDAQ:TMDX opened at $88.24 on Friday. The company has a fifty day simple moving average of $79.61 and a 200 day simple moving average of $93.17. The firm has a market cap of $3.05 billion, a PE ratio of 23.91, a price-to-earnings-growth ratio of 0.92 and a beta of 2.14. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62. TransMedics Group has a 12-month low of $60.10 and a 12-month high of $156.00.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Canaccord Genuity Group increased their target price on TransMedics Group from $95.00 to $120.00 and gave the company a “buy” rating in a research note on Friday. Needham & Company LLC increased their target price on TransMedics Group from $106.00 to $110.00 and gave the stock a “buy” rating in a report on Friday. Weiss Ratings upgraded shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. TD Cowen restated a “buy” rating and set a $120.00 price target on shares of TransMedics Group in a report on Tuesday, September 8th. Finally, UBS Group reduced their price objective on shares of TransMedics Group from $80.00 to $77.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 5th. Five investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to MarketBeat, TransMedics Group has an average rating of “Hold” and an average target price of $118.60.

Key Stories Impacting TransMedics Group

Here are the key news stories impacting TransMedics Group this week:

• Positive Sentiment: Third-quarter revenue was $203.0 million, up 41.1% year over year and above the roughly $178 million consensus. Adjusted earnings of $0.51 per share also beat estimates of about $0.30, supporting the growth outlook. TransMedics Q3 2026 results
• Positive Sentiment: TransMedics raised its 2026 revenue guidance to $764 million–$774 million, a signal of confidence in continued business growth. Needham also raised its price target from $106 to $110 and reiterated a Buy rating. Revenue guidance and catalyst update Needham recommendations
• Neutral Sentiment: Unusual options activity followed the earnings report, indicating heightened trading interest but not a clear directional signal. Unusual options activity report
• Negative Sentiment: ENHANCE Part B and DENOVO catalysts have shifted to early 2027, delaying potential near-term developments. EPS was also below the year-ago quarter’s $0.66, despite beating analyst estimates. Catalyst timing update

Insiders Place Their Bets

In other TransMedics Group news, Director David Weill purchased 1,336 shares of the firm’s stock in a transaction dated Friday, September 11th. The shares were bought at an average price of $81.63 per share, for a total transaction of $109,057.68. Following the purchase, the director owned 16,392 shares in the company, valued at approximately $1,338,078.96. This trade represents a 8.87% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 6.90% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.